Improvement of outcome prediction of hospitalized patients with COVID-19 by a dual marker strategy using high-sensitive cardiac troponin I and copeptin

Kaufmann, Christoph C; Ahmed, Amro; Kassem, Mona; Freynhofer, Matthias K.; Jäger, Bernhard; Aicher, Gabriele; Equiluz-Bruck, Susanne; Spiel, Alexander; Vafai-Tabrizi, Florian; Gschwantler, Michael; Fasching, Peter; Wojta, Johann; Giannitsis, Evangelos; Huber, Kurt

doi:10.1007/s00392-021-01970-4

Cited by 4 publications

(1 citation statement)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The addition of both biomarkers to clinically established risk scores in COVID-19 (e.g., 4C Clinical deterioration index) improved C-statistics and net reclassification indices, suggesting incremental prognostic information is provided by this dual biomarker strategy upon admission. Our study also showed that patients with increased copeptin and hs-cTnI were more likely to have ECG abnormalities, such as atrial fibrillation, bundle branch block, or low voltage [124]. A study from Switzerland also showed a significant association between copeptin and short-term mortality in a smaller study population of 74 patients.…”

Section: Copeptinsupporting

confidence: 68%

Biomarkers Associated with Cardiovascular Disease in COVID-19

Kaufmann

Ahmed

Burger

et al. 2022

Cells

Self Cite

View full text Add to dashboard Cite

Coronavirus disease-19 (COVID-19) emerged late December 2019 in the city of Wuhan, China and has since spread rapidly all over the world causing a global pandemic. While the respiratory system is the primary target of disease manifestation, COVID-19 has been shown to also affect several other organs, making it a rather complex, multi-system disease. As such, cardiovascular involvement has been a topic of discussion since the beginning of the COVID-19 pandemic, primarily due to early reports of excessive myocardial injury in these patients. Treating physicians are faced with multiple challenges in the management and early triage of patients with COVID-19, as disease severity is highly variable ranging from an asymptomatic infection to critical cases rapidly deteriorating to intensive care treatment or even fatality. Laboratory biomarkers provide important prognostic information which can guide decision making in the emergency department, especially in patients with atypical presentations. Several cardiac biomarkers, most notably high-sensitive cardiac troponin (hs-cTn) and N-terminal pro-B-type natriuretic peptide (NT-proBNP), have emerged as valuable predictors of prognosis in patients with COVID-19. The purpose of this review was to offer a concise summary on prognostic cardiac biomarkers in COVID-19 and discuss whether routine measurements of these biomarkers are warranted upon hospital admission.

show abstract

Section: Copeptinsupporting

confidence: 68%

Biomarkers Associated with Cardiovascular Disease in COVID-19

Kaufmann

Ahmed

Burger

et al. 2022

Cells

Self Cite

View full text Add to dashboard Cite

show abstract

Innate immune responses in COVID-19

Jacotot

Talamini

Bonam

et al. 2023

Autoimmunity, COVID-19, Post-Covid19 Syndrome and COVID-19 Vaccination

View full text Add to dashboard Cite

Key role of laboratory diagnostics of cardiovascular system injury in COVID‑19

Tazina,

Antipova,

Fedorova

et al. 2024

Medicinskij alfavit

View full text Add to dashboard Cite

This literature review examines data characterizing the clinical significance of the most informative laboratory markers, which make it possible not only to promptly identify the pathology of the cardiovascular system, but also to assess the risk of adverse outcomes of coronavirus infection. The most studied markers are hsTnI, NT-proBNP, D-dimer. Promising laboratory markers that require comprehensive study include osteopontin, stimulating growth factor ST2, Gal-3, copeptin, endothelin-1. With all the variety of pathological conditions that are accompanied by an increase in the concentrations of these markers, they can be considered as indicators that undoubtedly deserve close attention when assessing patients with COVID-19.

show abstract

Improvement of outcome prediction of hospitalized patients with COVID-19 by a dual marker strategy using high-sensitive cardiac troponin I and copeptin

Cited by 4 publications

References 32 publications

Biomarkers Associated with Cardiovascular Disease in COVID-19

Biomarkers Associated with Cardiovascular Disease in COVID-19

Innate immune responses in COVID-19

Key role of laboratory diagnostics of cardiovascular system injury in COVID‑19

Contact Info

Product

Resources

About